A Phase I, Randomised, Open-Label, Single and Multiple Ascending Dose (Twice-Daily), Incomplete Block, Cross-Over Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide Administered by Inhalation in Healthy Chinese Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2018
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 28 Nov 2018 Planned End Date changed from 16 Jan 2019 to 16 Jul 2019.
- 28 Nov 2018 Planned primary completion date changed from 16 Jan 2019 to 16 Jul 2019.
- 28 Nov 2018 Planned initiation date changed from 16 Nov 2018 to 17 May 2019.